

Figure S1: nAb responses in I+V- HCWs in Madagascar according reported wave of infection. (A) Percentage of unvaccinated HCWs who declared having been infected only once: during waves 1, 2 and 3. (B-C) SARS-CoV-2 specific nAb titers according to the declared wave of infection in individuals infected just once. (B) against W, (C) against BA.2. * *p*-value <0.05; *** *p*-value <0.0001, ns: non significant




Figure S2: Neutralizing antibody responses in the Cameroonian HCW sub-populations. (A-B) SARS-CoV-2 specific nAb titers according to the type of immunization. (A) against WT, (B) against BA.2. populational groups are indicated on the X axis and neutralization titers on the Y axis. Data were compared using the Mann-Whitney test. Each dot represents an independent sample. (C-D) Percentage of individuals having nAb titers above the calculated threshold. (C) against WT, (D) against BA.2. Data were compared using the Fischer's exact test. * *p*-value <0.05 ; ** *p*-value <0.001; *** *p*-value <0.0001; ns: non significative

Vaccines		Madagascar n(%)	RCA n(%)	Cameroon n(%)
ASTRAZENECA	Dose1	131(39,82%)	82 (70,69%)	7 (5,69%)
	Dose2	117(35,56%)	3 (50%)	
	Dose3	4(1,22%)		
Johnson&Johnson	Dose1	176(53,5%)	30 (25,86%)	85 (69,10%)
	Dose2	7(2,13%)	5 (83,33%)	2 (1,63%)
	Dose3	2(0,61%)		
SINOPHARM	Dose1	1(0,3%)	2 (1,72%)	29 (23,57%)
	Dose2	1(0,3%)		
	Dose3			
Sinovac	Dose1	1(0,3%)		
	Dose2			
	Dose3			
Moderna	Dose1	1(0,3%)		
	Dose2	2(0,61%)		
	Dose3	1(0,3%)		
Pfizer/BioNTech	Dose1	19(5,78%)		
	Dose2	28(8,51%)		
	Dose3	43(13,07%)		
Sputnik V	Dose1			
	Dose2	1(0,3%)		
	Dose3			
Unknow	Dose1		2 (1,72%)	2 (1,62%)
	Dose2		1 (16,66%)	
	Dose3			

Table S1: . Descriptive table of vaccines received during the study. The percentage corresponds to the number of individuals among the vaccinated individuals who received a type of vaccine (Dose 1: first vaccination, Dose 2: Second vaccination, Dose 3: Third vaccination).